# A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

> **NCT02431702** · PHASE3 · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 337 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Haloperidol
- **DRUG:** Olanzapine
- **DRUG:** Oral Paliperidone ER
- **DRUG:** Perphenazine
- **DRUG:** Quetiapine
- **DRUG:** Oral Risperidone
- **DRUG:** Paliperidone Palmitate Injection (PP1M)
- **DRUG:** Paliperidone Palmitate Injection (PP3M)

## Key facts

- **NCT ID:** NCT02431702
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-08
- **Primary completion:** 2019-11-12
- **Final completion:** 2019-11-12
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431702, "A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02431702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*